NASDAQ:PRTK - Paratek Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.01 -0.25 (-3.99 %)
(As of 12/17/2018 07:14 AM ET)
Previous Close$6.26
Today's Range$5.94 - $6.23
52-Week Range$5.94 - $19.35
Volume635,465 shs
Average Volume267,817 shs
Market Capitalization$193.17 million
P/E Ratio-1.82
Dividend YieldN/A
Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:PRTK
Previous SymbolNASDAQ:TSPT


Debt-to-Equity Ratio3.97
Current Ratio11.39
Quick Ratio11.39


Trailing P/E Ratio-1.82
Forward P/E Ratio-1.73
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.62 million
Price / Sales15.31
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.65 per share
Price / Book2.27


EPS (Most Recent Fiscal Year)($3.30)
Net Income$-89,060,000.00
Net Margins-2,155.03%
Return on Equity-132.55%
Return on Assets-44.56%


Outstanding Shares32,140,000
Market Cap$193.17 million

Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) released its quarterly earnings results on Tuesday, November, 6th. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.85) by $0.16. The specialty pharmaceutical company had revenue of $0.05 million for the quarter, compared to analysts' expectations of $5.89 million. Paratek Pharmaceuticals had a negative net margin of 2,155.03% and a negative return on equity of 132.55%. View Paratek Pharmaceuticals' Earnings History.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Paratek Pharmaceuticals.

What price target have analysts set for PRTK?

8 equities research analysts have issued 12-month price targets for Paratek Pharmaceuticals' shares. Their forecasts range from $13.00 to $50.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $27.8333 in the next twelve months. This suggests a possible upside of 363.1% from the stock's current price. View Analyst Price Targets for Paratek Pharmaceuticals.

What is the consensus analysts' recommendation for Paratek Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Paratek Pharmaceuticals.

What are Wall Street analysts saying about Paratek Pharmaceuticals stock?

Here are some recent quotes from research analysts about Paratek Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company's lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. " (8/3/2018)
  • 2. Cantor Fitzgerald analysts commented, ". Post a quarter of solid execution and ahead of the AdCom on 8/8/18 as well as what we expect to be an approval for omadacycline, we are reiterating our OW rating and 12-month price target of $50. We like PRTK because it is well capitalized (including the convertible debt raise and incoming milestones), de-risked with three positive Phase 3 trials (in an oral only skin trial) and has a diversified pipeline (omadacycline for cUTI, uUTI, Sarecycline, etc.). We anticipate two product approvals for PRTK in 2H18, omadacycline and Sarecycline." (8/2/2018)

Has Paratek Pharmaceuticals been receiving favorable news coverage?

Press coverage about PRTK stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Paratek Pharmaceuticals earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are some of Paratek Pharmaceuticals' key competitors?

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael F. Bigham, Chairman & CEO (Age 60)
  • Dr. Evan Loh, Pres, Chief Medical Officer, COO & Director (Age 59)
  • Mr. Douglas W. Pagán, Chief Financial Officer (Age 46)
  • Mr. William M. Haskel, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. Adam Woodrow, Chief Commercial Officer & VP (Age 51)

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.44%), Highland Capital Management LP (8.26%), Vanguard Group Inc (4.33%), Vanguard Group Inc. (4.33%), C WorldWide Group Holding A S (1.60%) and Water Island Capital LLC (1.37%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Douglas W Pagan, Evan Loh, Michael Bigham, Robert S Radie and William M Haskel. View Institutional Ownership Trends for Paratek Pharmaceuticals.

Which institutional investors are selling Paratek Pharmaceuticals stock?

PRTK stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Man Group plc, Commonwealth of Pennsylvania Public School Empls Retrmt SYS, Virtus ETF Advisers LLC, C WorldWide Group Holding A S, Royce & Associates LP and Credit Suisse AG. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Douglas W Pagan, Evan Loh, Michael Bigham, Robert S Radie and William M Haskel. View Insider Buying and Selling for Paratek Pharmaceuticals.

Which institutional investors are buying Paratek Pharmaceuticals stock?

PRTK stock was acquired by a variety of institutional investors in the last quarter, including Highland Capital Management LP, Dimensional Fund Advisors LP, Water Island Capital LLC, BlackRock Inc., Wedbush Securities Inc., Baird Financial Group Inc., General American Investors Co. Inc. and Vanguard Group Inc. View Insider Buying and Selling for Paratek Pharmaceuticals.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $6.01.

How big of a company is Paratek Pharmaceuticals?

Paratek Pharmaceuticals has a market capitalization of $193.17 million and generates $12.62 million in revenue each year. The specialty pharmaceutical company earns $-89,060,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis. Paratek Pharmaceuticals employs 83 workers across the globe.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]

MarketBeat Community Rating for Paratek Pharmaceuticals (NASDAQ PRTK)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  253 (Vote Underperform)
Total Votes:  564
MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote "Outperform" if you believe PRTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/17/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel